Chronic obstructive pulmonary disease (COPD), a condition that affects more than 14 million U.S. adults, is marked by damage ...
In September 2023, The US Food and Drug Administration has approved Krystal Biotech’s Investigational New Drug (IND) application for a Phase I clinical trial of KB408, an investigational treatment for ...